Stephens Consulting, LLC Recursion Pharmaceuticals, Inc. Transaction History
Stephens Consulting, LLC
- $400 Billion
- Q4 2024
A detailed history of Stephens Consulting, LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Stephens Consulting, LLC holds 67 shares of RXRX stock, worth $530. This represents 0.0% of its overall portfolio holdings.
Number of Shares
67Holding current value
$530% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RXRX
# of Institutions
302Shares Held
241MCall Options Held
1.35MPut Options Held
2.32M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.3MShares$256 Million1.91% of portfolio
-
Baillie Gifford & CO24.9MShares$197 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.3MShares$192 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$137 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$122 Million1.41% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.43B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...